Impact of Increased Use of Single-Inhaler Triple Therapies on COPD Exacerbation Rates, Mortality, and Total Costs: PROMETHEUS France
The model shows that increased SITT use in France, in line with recent recommendations, could be associated with a reduction in exacerbation rates, mortality, and costs in patients with COPD.
Authors
- Melissa Caplen
- Jennifer Carioto
- Gabriel Thabut (ORCID: https://orcid.org/0000-0001-7218-7917)
- David Koskas
- John Bell (ORCID: https://orcid.org/0000-0001-9307-1235)
- Bruce Pyenson (ORCID: https://orcid.org/0000-0003-0416-9391)
- Prachi Bhatt
- C. Fabry-Vendrand (ORCID: https://orcid.org/0000-0001-8786-7843)
- Gaëtan Deslée (ORCID: https://orcid.org/0000-0002-4919-5916)
- Pierre‐Régis Burgel (ORCID: https://orcid.org/0000-0003-0903-9828)
- Héloïse Russo
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Hôpital Cochin (FR)
- Centre Hospitalier Universitaire de Reims (FR)
- AstraZeneca (France) (FR)
- AstraZeneca (Poland) (PL)
- Institut Cochin (FR)
- Milliman (United States) (US)
- Université de Reims Champagne-Ardenne (FR)
Publication Details
- Journal
- International Journal of COPD
- Published
- 2025-11-01
- DOI
- https://doi.org/10.2147/copd.s539055
- Citations
- 1
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- AstraZeneca
- Sanofi
- Insmed